Lack Of Harmonization In ICH Q12 Draft Guideline Draws Fire In US

Major pharmaceutical industry groups in the US, like their counterparts in the EU, are concerned that the draft ICH Q12 guideline does not align with the established legal framework in certain ICH regions, including the EU, in terms of implementing key concepts such as established conditions and product lifecycle management.

Businessman sinking in heap of documents and asking for help

Major pharmaceutical industry groups in the US say that while they support in principle many of the core principles of the draft ICH Q12 guideline on lifecycle management and post-approval changes, they are concerned about its implementation, and about its incompatibility with the established legal framework in certain ICH regions, including the EU.

They complain that not having a global framework for some core concepts of ICH Q12 like established conditions (ECs) and...

More from Manufacturing

More from Compliance

UK MHRA: Bacteriophage Developers Wanted ‘More Clarity’ On UK Framework

 

Julian Beach, interim executive director of healthcare quality and access at the UK drug regulator, the MHRA, tells the Pink Sheet how the agency is responding to increased efforts to develop bacteriophage therapies.

Novo, Lilly Ad Challenges Cause Discontinued Claims For Compounded GLP-1s

 
• By 

Two pharmacies, a medical spa and a telehealth company voluntarily removed efficacy, safety and quality claims for compounded GLP-1 products after innovator companies filed challenges with the National Advertising Division.

EU Emergency Response Authority Needs Bigger Budget To Address Health Threats, Says Industry

 

The EU must renew the mandate of its Health Emergency Response Authority to support medicine stockpiles and enable agile manufacturing to combat antimicrobial resistance and chemical, biological, radiological and nuclear threats, says trade organization EUCOPE.